-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pacific Biosciences said after the close on Tuesday that its third-quarter revenue increased by 83%, driven by sequencing equipment and consumables
According to reports, product revenue reached 30.
Among product revenues, instrument revenue was $15.
Christian Henry, CEO of PacBio, also said that the number of installations of Sequel II/IIe hit a record high
Henry said on the conference call that his Chinese partner Berry and Kang recently received a medical device registration inspection report issued by the China Medical Device Quality Supervision and Inspection Center, stating that the Sequel II CNDx instrument has passed the technical requirements
From a regional perspective, income in the Americas reached 19.
PacBio's research and development expenses this quarter reached 27.
The company’s net income in the third quarter was $16.
Susan Kim, chief financial officer of PacBio, said that the company's full-year revenue forecast for 2021 will remain at US$128 million to US$132 million, an increase of 62% to 67%